Esperion Therapeutics

Esperion Therapeutics, Inc.
Public
Traded as NASDAQ: ESPR
Industry Pharmaceutical
Founded 2008 (2008)
Founder
  • Dr. Roger Newton
Headquarters Ann Arbor, MI
Key people
Timothy M. Mayleben (President & CEO)
  • Decrease(US$26.1 million)loss (2013)
  • (US$11.7 million)loss (2012)
Total assets
  • IncreaseUS$78.3 million (2013)
  • US$7.31 million (2012)
Website Esperion.com
Footnotes / references
financial information[1]:F-3,4

Esperion Therapeutics, Inc. is a public, American pharmaceutical company focused on the development of a first-in-class, orally available, small molecule designed to significantly lower elevated levels of LDL-C - with the reduced potential for muscle-related side effects associated with statin use. The company is headquartered in Ann Arbor, MI.

History

Pfizer acquired the original Esperion in 2004 for US$1,300,000,000 as a defensive move to prevent ETC-216 from falling into competitors' hands.[2]:165 Two years later, in 2006, Pfizer decided to kill the Esperion organization and development of ETC-216. In May 2008, Dr. Roger Newton, Esperion's founder and chief scientific officer, who co-discovered the statin marketed as Lipitor® — the most commonly prescribed LDL-C lowering therapy in the world and best-selling drug in the pharmaceutical industry’s history, raised sufficient capital to acquire rights to ETC-1002 and Esperion from Pfizer, thereby leading to a second independent period for the company.[2]:165[3][4] In June 2013, Esperion became a public company again through an initial public offering.[5] As of April 2014, Esperion was traded on NASDAQ under the symbol "ESPR".[6]

Product Candidates

ETC-1002

ETC-1002 is an innovative, first-in-class, orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. ETC-1002 is absorbed rapidly in the small intestine and enters the liver through cell surface receptors different from those transporters that selectively take up statins.

Once in the liver, ETC-1002 inhibits ACL. Pre-clinical studies show that in the liver, ETC-1002 is converted to a derivative coenzyme, or ETC-1002-CoA, which directly inhibits ACL, a key enzyme that supplies substrate for cholesterol and fatty acid synthesis in the liver.

To date, Esperion has studied ETC-1002 in ten completed clinical trials and treated approximately 726 patients with ETC-1002 across completed Phase 1 and 2 studies.

References

  1. "Esperion Therapeutics, Inc.". EDGAR. Form 10-K. U.S. Securities and Exchange Commission. March 13, 2014. Commission File Number:001-35986.
  2. 1 2 Li, Jie Jack (2009). Triumph of the Heart: The Story of Statins. Oxford University Press. ISBN 9780195323573.
  3. "History". Esperion Therapeutics. Archived from the original on April 29, 2012.
  4. Catherine Shaffer (2008). "Pfizer jettisons Esperion". Nat. Biotechnol. 26 (7): 724–725. doi:10.1038/nbt0708-724.
  5. Huggett, Brady (December 2013). "Burning Bright". Nat. Biotechnol. 31 (12). pp. 1068–71.
  6. "ESPR stock quote". NASDAQ. Retrieved April 22, 2014.

Further reading

This article is issued from Wikipedia - version of the 10/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.